



Deciphera Pharmaceuticals Announces Appointment of Kapil Bhalla, MD to its Scientific Advisory Board

June 11, 2012

Deciphera Pharmaceuticals today announced the appointment of Dr. Kapil Bhalla, MD, to its Scientific Advisory Board. Dr. Bhalla brings years of experience in oncology translational research to his role with Deciphera. Currently, he is Deputy Director of the University of Kansas Cancer Center, Drug Discovery, Delivery and Experimental Therapeutics Program, Schutte/Speas Endowed Professor of Medicine & Kansas Bioscience Authority Eminent Scholar. Dr. Bhalla is an internationally recognized leader and physician-scientist in the field of cancer biology and targeted drug therapy. His research interests are the biologic basis and mechanism of action/resistance of novel targeted therapeutics of leukemia, lymphoma and breast cancer, especially related to cancer epigenomics, chaperone biology and client oncoprotein kinases. Dr. Bhalla serves as a member of the Basic Mechanisms of Cancer Therapeutics (BMCT) Study Section of the National Institutes of Health and also serves as a member of the Investigational Drug Steering Committee (IDSC) and Target Development Scientific Advisory Committee of the National Cancer Institute. Prior to joining the University of Kansas Cancer Center, Bhalla was the founding Director of the Medical College of Georgia Cancer Center, where he was a Georgia Research Alliance Eminent Scholar in Cancer and occupied the Cecil F. Whitaker, Jr., MD Chair in Cancer. A 1976 graduate of the University of Delhi's Maulana Azad Medical College in India, Dr. Bhalla completed his fellowship in hematology and oncology in 1983 at the Columbia University College of Physicians and Surgeons in New York, where he served on the

faculty until 1989. He has also served as a tenured Professor on the faculties of the Medical University of South Carolina, Emory University, University of South Florida, and the Medical College of Georgia. Dr. Bhalla is the author of more than 180 scholarly articles on cancer research and clinical trials. He also serves as a member of the Editorial Boards of Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, Molecular Cancer, PLoS ONE, and Cancer Biology and Therapy.